[go: up one dir, main page]

EA200970810A1 - Модифицированные полипептиды рецептора активина и их применение - Google Patents

Модифицированные полипептиды рецептора активина и их применение

Info

Publication number
EA200970810A1
EA200970810A1 EA200970810A EA200970810A EA200970810A1 EA 200970810 A1 EA200970810 A1 EA 200970810A1 EA 200970810 A EA200970810 A EA 200970810A EA 200970810 A EA200970810 A EA 200970810A EA 200970810 A1 EA200970810 A1 EA 200970810A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
receptor polypeptides
activin receptor
proteins
modified activin
Prior art date
Application number
EA200970810A
Other languages
English (en)
Other versions
EA020510B1 (ru
Inventor
Йонгхун Сан
Лей-тинг Тони Тэм
Эйчкью Хэн
Кейт Су-ньюнг Квак
Ксяолан Жоу
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200970810A1 publication Critical patent/EA200970810A1/ru
Publication of EA020510B1 publication Critical patent/EA020510B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)

Abstract

В настоящем изобретении предлагают вариантные полипептиды и белки растворимого рецептора активина IIB, способные связывать активин А, миостатин или GDF-11 и ингибировать их активность. В настоящем изобретении также предлагают полинуклеотиды, векторы и клетки хозяина, способные продуцировать вариантные полипептиды и белки. Также предложены композиции и способы лечения атрофии мышц и других заболеваний и нарушений.
EA200970810A 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение EA020510B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90545907P 2007-03-06 2007-03-06
US6547408P 2008-02-11 2008-02-11
PCT/US2008/003119 WO2008109167A2 (en) 2007-03-06 2008-03-06 Variant activin receptor polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
EA200970810A1 true EA200970810A1 (ru) 2010-06-30
EA020510B1 EA020510B1 (ru) 2014-11-28

Family

ID=39739001

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200970810A EA020510B1 (ru) 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение
EA201490822A EA201490822A1 (ru) 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201490822A EA201490822A1 (ru) 2007-03-06 2008-03-06 Модифицированные полипептиды рецептора активина и их применение

Country Status (29)

Country Link
US (5) US7947646B2 (ru)
EP (2) EP2132314B1 (ru)
JP (1) JP5496682B2 (ru)
KR (5) KR101633728B1 (ru)
CN (2) CN105924516A (ru)
AR (1) AR065611A1 (ru)
AU (1) AU2008223338C9 (ru)
BR (1) BRPI0808332A2 (ru)
CA (1) CA2679841C (ru)
CL (2) CL2008000664A1 (ru)
CR (2) CR11054A (ru)
CY (1) CY1118857T1 (ru)
DK (1) DK2132314T3 (ru)
EA (2) EA020510B1 (ru)
ES (1) ES2613043T3 (ru)
HR (1) HRP20170323T1 (ru)
HU (1) HUE032260T2 (ru)
IL (2) IL200605A (ru)
LT (1) LT2132314T (ru)
MX (3) MX2009009495A (ru)
NZ (1) NZ579369A (ru)
PE (3) PE20171325A1 (ru)
PH (1) PH12013502308A1 (ru)
PL (1) PL2132314T3 (ru)
PT (1) PT2132314T (ru)
RS (1) RS55726B1 (ru)
SI (1) SI2132314T1 (ru)
TW (3) TW201718635A (ru)
WO (1) WO2008109167A2 (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20160137665A (ko) 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
CN101511871B (zh) 2006-09-05 2012-07-18 伊莱利利公司 抗肌肉生长抑制因子抗体
ES2396734T3 (es) 2006-12-18 2013-02-25 Acceleron Pharma, Inc. Antagonistas de ACTIVINA-ACTRII y sus usos para tratar la anemia
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5237970B2 (ja) 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
AU2013216639B2 (en) * 2008-11-26 2016-05-05 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
AU2016210719B2 (en) * 2008-11-26 2018-03-29 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
PT2370463T (pt) * 2008-11-26 2016-11-04 Amgen Inc Variante estabilizada do receptor da activina iib
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
MX2011011352A (es) 2009-04-27 2011-11-18 Novartis Ag Composiciones y metodos para aumentar el crecimiento muscular.
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
JP5836961B2 (ja) 2009-11-03 2015-12-24 アクセルロン ファーマ， インコーポレイテッド 脂肪肝疾患を処置するための方法
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
JP5841608B2 (ja) 2010-11-12 2016-01-13 コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ 口腔ケア製品およびその使用方法および製造方法
DK2726099T3 (en) * 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
PT2780368T (pt) 2011-11-14 2018-03-22 Regeneron Pharma Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
ES2779698T3 (es) 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
EA201492282A1 (ru) 2012-06-11 2015-07-30 Амген Инк. Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
CN105431455A (zh) 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
EA201591825A1 (ru) * 2013-03-15 2016-05-31 Амген Инк. Антагонизм миостатина у субъектов - людей
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015073396A1 (en) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
US20170202909A1 (en) * 2014-06-13 2017-07-20 Santa Maria Biotherapeutics, Inc. Formulated Receptor Polypeptides and Related Methods
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
TN2017000217A1 (en) * 2014-12-08 2018-10-19 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
EP3256148A1 (en) 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
US9744985B2 (en) 2015-02-17 2017-08-29 Hyundai Motor Company Rack bar unit of vehicle steering device
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
US10227392B2 (en) 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
JP6810702B2 (ja) 2015-04-06 2021-01-06 アクセルロン ファーマ インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
MA49661A (fr) 2015-04-15 2020-06-03 Regeneron Pharma Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
CN109310742B (zh) 2016-01-06 2022-12-02 哈佛学院校长同事会 使用gdf11的治疗防止体重增加、提高葡萄糖耐量并减轻脂肪肝
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
IL275936B2 (en) 2018-01-12 2025-09-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of using them
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
EP3790572A4 (en) 2018-05-09 2022-03-16 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2023108137A1 (en) * 2021-12-10 2023-06-15 Biogen Ma Inc. Modified actriib proteins and methods of use thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899886A (en) * 1959-08-18 rodth
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5349966A (en) 1976-10-18 1978-05-06 Hitachi Ltd Manufacture of semiconductor integrated circuit
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
DK0521510T3 (da) * 1991-07-05 1997-05-12 Nestle Sa Stiv kaffepatron og fremgangsmåde til fremstilling heraf
EP0521187B1 (fr) * 1991-07-05 1995-11-02 Societe Des Produits Nestle S.A. Dispositif d'extraction de cartouches adaptable à toute machine espresso
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
DE69232604T2 (de) 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5827733A (en) 1993-03-19 1998-10-27 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 (GDF-8) and polynucleotides encoding same
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
JPH10511840A (ja) 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド 形態形成タンパク質特異細胞表面レセプターおよびその使用
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
JP2000262405A (ja) * 1999-03-18 2000-09-26 Soc Prod Nestle Sa 飲料抽出用密封カートリッジ
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
TWI236360B (en) * 2000-06-30 2005-07-21 Nestle Sa Capsule cage
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DE60009495T2 (de) * 2000-09-26 2004-08-19 Société des Produits Nestlé S.A. Packung zur Getränkezubereitung mit Extraktion unter Druck
EP1203554A1 (fr) * 2000-11-03 2002-05-08 Societe Des Produits Nestle S.A. Dispositif pour l'extraction d'une substance alimentaire contenue dans un élément de recharge
ATE274321T1 (de) * 2000-11-28 2004-09-15 Nestle Sa Perkolationsvorrichtung
US20050188854A1 (en) * 2002-02-07 2005-09-01 The Coca-Cola Co. Coffee and tea dispenser
US6786134B2 (en) * 2002-02-07 2004-09-07 The Coca-Cola Company Coffee and tea dispenser
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
FR2842092B1 (fr) * 2002-07-12 2004-12-24 Seb Sa Machine a cafe fonctionnant avec des doses
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
US20060196364A1 (en) * 2003-07-22 2006-09-07 The Coca-Cola Company Coffee & Tea Pod
US8327754B2 (en) * 2003-07-22 2012-12-11 The Coca-Cola Company Coffee and tea pod
PT2821067T (pt) 2003-09-12 2017-12-01 Amgen Inc Formulação de cinacalcet de dissolução rápida
US7074445B2 (en) * 2003-10-30 2006-07-11 Frito-Lay North America, Inc. Method for adhering large seasoning bits to a food substrate
EP1682582B1 (en) 2003-11-13 2011-08-31 Hanmi Holdings Co., Ltd Method for the mass production of immunoglobulin constant region
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
GB2411106B (en) * 2004-02-17 2006-11-22 Kraft Foods R & D Inc Cartridge for the preparation of beverages
SI1750683T1 (sl) 2004-04-23 2013-04-30 Amgen Inc. M/S 27-4-A, Amgen Inc. Formulacije s podaljĺ anim sproĺ äśanjem
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
GB2416480B (en) * 2004-07-27 2007-12-27 Kraft Foods R & D Inc A system for the preparation of beverages
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
EP1640756A1 (en) * 2004-09-27 2006-03-29 Barco N.V. Methods and systems for illuminating
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP1933871B1 (en) 2005-09-07 2013-04-24 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
DE602005008610D1 (de) * 2005-10-14 2008-09-11 Nestec Sa Kapsel zur Bereitung eines Getränks
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20080014860A1 (en) * 2006-07-14 2008-01-17 Lynn Byron Heitman Method and apparatus for eliminating register boxes, improving penetration sealing, improving airflow and reducing the labor costs to install ceiling registers
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
ES2396734T3 (es) 2006-12-18 2013-02-25 Acceleron Pharma, Inc. Antagonistas de ACTIVINA-ACTRII y sus usos para tratar la anemia
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
US8431175B2 (en) * 2007-06-05 2013-04-30 Nestec S.A. Method for preparing a beverage or food liquid and system using brewing centrifugal force
JP5082676B2 (ja) * 2007-08-23 2012-11-28 株式会社サタケ 光学式穀物選別機
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
EP3363453A1 (en) 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
CN105146525A (zh) * 2008-07-08 2015-12-16 雀巢产品技术援助有限公司 部分受控的营养系统和使用胶囊的方法
US8151694B2 (en) * 2008-08-01 2012-04-10 Keurig, Incorporated Beverage forming apparatus with centrifugal pump
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ES2550307T3 (es) * 2008-09-02 2015-11-06 Nestec S.A. Dispositivo de producción controlada de bebidas usando fuerzas centrífugas
PT2370463T (pt) 2008-11-26 2016-11-04 Amgen Inc Variante estabilizada do receptor da activina iib
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
MX2011011352A (es) 2009-04-27 2011-11-18 Novartis Ag Composiciones y metodos para aumentar el crecimiento muscular.
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
WO2011085165A2 (en) 2010-01-08 2011-07-14 The Brigham And Women's Hospital, Inc. Ca-125 immune complexes as biomarkers of ovarian cancer
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
EP2802308A1 (en) 2012-01-13 2014-11-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CN101679980A (zh) 2010-03-24
SI2132314T1 (sl) 2017-03-31
AU2008223338C1 (en) 2013-06-20
KR101633727B1 (ko) 2016-06-28
CN101679980B (zh) 2016-05-11
PE20130615A1 (es) 2013-07-01
IL200605A (en) 2016-10-31
EP2132314A2 (en) 2009-12-16
PE20171325A1 (es) 2017-09-11
US20180072791A1 (en) 2018-03-15
KR101633728B1 (ko) 2016-06-28
US10407487B2 (en) 2019-09-10
ES2613043T3 (es) 2017-05-22
US7947646B2 (en) 2011-05-24
EA201490822A1 (ru) 2014-11-28
MX348286B (es) 2017-06-02
KR101428344B1 (ko) 2014-08-13
CA2679841A1 (en) 2008-09-12
JP5496682B2 (ja) 2014-05-21
AU2008223338C9 (en) 2013-07-04
IL248322A0 (en) 2016-11-30
CA2679841C (en) 2022-03-08
US8716459B2 (en) 2014-05-06
CR11054A (es) 2009-10-30
MX2009009495A (es) 2009-09-15
CL2015003139A1 (es) 2016-07-15
KR20090127146A (ko) 2009-12-09
TWI454479B (zh) 2014-10-01
US20160264644A1 (en) 2016-09-15
MX389715B (es) 2025-03-20
TW201718635A (zh) 2017-06-01
LT2132314T (lt) 2017-03-27
US9447165B2 (en) 2016-09-20
TW201441254A (zh) 2014-11-01
AU2008223338B2 (en) 2012-12-20
US20140194355A1 (en) 2014-07-10
EA020510B1 (ru) 2014-11-28
EP3141605A1 (en) 2017-03-15
PE20081804A1 (es) 2009-02-21
PL2132314T3 (pl) 2017-07-31
RS55726B1 (sr) 2017-07-31
EP2132314B1 (en) 2016-11-30
DK2132314T3 (en) 2017-02-27
CR20150094A (es) 2015-04-14
KR20160075861A (ko) 2016-06-29
HUE032260T2 (en) 2017-09-28
IL200605A0 (en) 2011-08-01
WO2008109167A3 (en) 2009-06-18
CY1118857T1 (el) 2018-01-10
WO2008109167A2 (en) 2008-09-12
KR20140056393A (ko) 2014-05-09
HRP20170323T1 (hr) 2017-04-21
CL2008000664A1 (es) 2008-06-13
AR065611A1 (es) 2009-06-17
CN105924516A (zh) 2016-09-07
US20090227497A1 (en) 2009-09-10
US20110183897A1 (en) 2011-07-28
TWI573802B (zh) 2017-03-11
TW200846359A (en) 2008-12-01
CN101679980B8 (zh) 2017-02-22
PT2132314T (pt) 2017-03-02
PH12013502308A1 (en) 2015-12-02
KR20120065374A (ko) 2012-06-20
JP2010519931A (ja) 2010-06-10
BRPI0808332A2 (pt) 2014-07-08
NZ579369A (en) 2012-02-24
KR20150024444A (ko) 2015-03-06
US9809638B2 (en) 2017-11-07
AU2008223338A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
EA200970810A1 (ru) Модифицированные полипептиды рецептора активина и их применение
EA201491231A8 (ru) Варианты полипептидов рецептора активина и их применение
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201070996A1 (ru) Способы применения сопряженного с g-белком рецептора для идентификации стимуляторов секреции пептида yy(pyy) и соединений, пригодных для лечения состояний, модулируемых pyy
WO2008025020A3 (en) Cd30 binding agents and uses thereof
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA200971077A1 (ru) Гетероциклические модуляторы киназы
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2008103966A3 (en) Compositions and methods using toll-like receptors and unc93b
TW200602055A (en) Spray dried pharmaceutical compositions
MY155313A (en) Variant activin receptor polypeptides and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU